MA71370A - Inhibiteurs macrocycliques de kras pour le traitement du cancer - Google Patents
Inhibiteurs macrocycliques de kras pour le traitement du cancerInfo
- Publication number
- MA71370A MA71370A MA71370A MA71370A MA71370A MA 71370 A MA71370 A MA 71370A MA 71370 A MA71370 A MA 71370A MA 71370 A MA71370 A MA 71370A MA 71370 A MA71370 A MA 71370A
- Authority
- MA
- Morocco
- Prior art keywords
- macrocyclic
- cancer
- treatment
- kras inhibitors
- kras
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/504—Pyridazines; Hydrogenated pyridazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2022103694 | 2022-07-04 | ||
| CN2022124638 | 2022-10-11 | ||
| CN2023070765 | 2023-01-05 | ||
| CN2023087633 | 2023-04-11 | ||
| PCT/EP2023/068154 WO2024008610A1 (fr) | 2022-07-04 | 2023-07-03 | Inhibiteurs macrocycliques de kras pour le traitement du cancer |
| EP23738471.4A EP4551578A1 (fr) | 2022-07-04 | 2023-07-03 | Inhibiteurs macrocycliques de kras pour le traitement du cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA71370A true MA71370A (fr) | 2025-04-30 |
Family
ID=87155635
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA71370A MA71370A (fr) | 2022-07-04 | 2023-07-03 | Inhibiteurs macrocycliques de kras pour le traitement du cancer |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20250257075A1 (fr) |
| EP (1) | EP4551578A1 (fr) |
| JP (1) | JP2025522629A (fr) |
| KR (1) | KR20250029239A (fr) |
| CN (1) | CN119546612A (fr) |
| AR (1) | AR129819A1 (fr) |
| AU (1) | AU2023303814A1 (fr) |
| CA (1) | CA3261042A1 (fr) |
| CL (1) | CL2024004085A1 (fr) |
| CO (1) | CO2024017733A2 (fr) |
| CR (1) | CR20240563A (fr) |
| IL (1) | IL316867A (fr) |
| MA (1) | MA71370A (fr) |
| MX (1) | MX2024015363A (fr) |
| PE (1) | PE20250843A1 (fr) |
| TW (1) | TW202408507A (fr) |
| WO (1) | WO2024008610A1 (fr) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20240088A1 (es) | 2021-05-05 | 2024-01-16 | Revolution Medicines Inc | Inhibidores de ras |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| EP4596552A1 (fr) | 2022-09-29 | 2025-08-06 | Guangzhou Joyo Pharmatech Co., Ltd | Dérivé macrocyclique et son utilisation |
| PE20252395A1 (es) | 2023-02-14 | 2025-10-10 | Hoffmann La Roche | Compuestos triciclicos para el tratamiento de cancer |
| WO2024211712A1 (fr) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Composés macrocycliques condensés en tant qu'inhibiteurs de ras |
| CN121487951A (zh) | 2023-04-07 | 2026-02-06 | 锐新医药公司 | 大环ras抑制剂 |
| KR20260019479A (ko) | 2023-05-04 | 2026-02-10 | 레볼루션 메디슨즈, 인크. | Ras 관련 질환 또는 장애를 위한 병용 요법 |
| CN121889155A (zh) | 2023-08-07 | 2026-04-17 | 锐新医药公司 | 用于治疗ras蛋白相关疾病或病症的rmc-6291 |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (fr) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Inhibiteurs de ras |
| WO2025217307A1 (fr) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Procédés de prédiction de la réponse à un inhibiteur de ras(on) et polythérapies |
| WO2025240847A1 (fr) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Inhibiteurs de ras |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (fr) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Compositions thérapeutiques et procédés de gestion d'effets liés au traitement |
| WO2026006747A1 (fr) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Inhibiteurs de ras |
| WO2026015801A1 (fr) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Méthodes de traitement d'une maladie ou d'un trouble liés à ras |
| WO2026015790A1 (fr) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Méthodes de traitement d'une maladie ou d'un trouble lié à ras |
| WO2026015825A1 (fr) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Utilisation d'un inhibiteur de ras pour traiter le cancer du pancréas |
| WO2026015796A1 (fr) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Méthodes de traitement d'une maladie ou d'un trouble lié à ras |
| WO2026021499A1 (fr) * | 2024-07-24 | 2026-01-29 | 苏州泽璟生物制药股份有限公司 | Inhibiteur cycloalkyle ou hétérocyclique substitué par haloalkylène, son procédé de préparation et son utilisation |
| TW202615038A (zh) | 2024-08-07 | 2026-04-16 | 美商太斯萊特醫藥美國有限責任公司 | 包含拓樸異構酶有效載荷之靶向kras之共價誘導之藥物結合物 |
| WO2026035945A1 (fr) | 2024-08-07 | 2026-02-12 | Tesseract Medicines Us, Llc | Conjugués médicamenteux induits par covalence ciblant kras et comprenant une charge utile de topoisomérase |
| WO2026050446A1 (fr) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Inhibiteurs de ras |
| WO2026064520A1 (fr) | 2024-09-19 | 2026-03-26 | Tesseract Medicines Us, Llc | Conjugués médicamenteux à induction covalente ciblant kras et comprenant une charge utile inhibitrice de tubuline |
| WO2026064527A1 (fr) | 2024-09-19 | 2026-03-26 | Tesseract Medicines Us, Llc | Conjugués médicamenteux à induction covalente ciblant kras comprenant une charge utile d'inhibiteur de tubuline |
| WO2026072904A2 (fr) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions et méthodes de traitement du cancer du poumon |
| WO2026090116A2 (fr) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Inhibiteurs de ras |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (fr) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Utilisation d'inhibiteurs ras pour traiter un cancer |
| WO2026106912A1 (fr) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Inhibiteurs de ras |
| WO2026112260A1 (fr) | 2024-11-21 | 2026-05-28 | Revolution Medicines, Inc. | Inhibiteurs de ras |
| WO2026122764A2 (fr) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Inhibiteurs de ras |
| WO2026128688A2 (fr) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Inhibiteurs de ras |
| WO2026161839A1 (fr) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Inhibiteurs de ras |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2022005359A (es) * | 2019-11-04 | 2022-06-02 | Revolution Medicines Inc | Inhibidores de ras. |
| EP4208261A1 (fr) * | 2020-09-03 | 2023-07-12 | Revolution Medicines, Inc. | Utilisation d'inhibiteurs de sos1 pour traiter des malignités à mutations de shp2 |
-
2023
- 2023-07-03 AR ARP230101730A patent/AR129819A1/es unknown
- 2023-07-03 WO PCT/EP2023/068154 patent/WO2024008610A1/fr not_active Ceased
- 2023-07-03 KR KR1020257003428A patent/KR20250029239A/ko active Pending
- 2023-07-03 JP JP2025500043A patent/JP2025522629A/ja active Pending
- 2023-07-03 CA CA3261042A patent/CA3261042A1/fr active Pending
- 2023-07-03 PE PE2024003109A patent/PE20250843A1/es unknown
- 2023-07-03 CN CN202380051654.4A patent/CN119546612A/zh active Pending
- 2023-07-03 CR CR20240563A patent/CR20240563A/es unknown
- 2023-07-03 IL IL316867A patent/IL316867A/en unknown
- 2023-07-03 AU AU2023303814A patent/AU2023303814A1/en active Pending
- 2023-07-03 MA MA71370A patent/MA71370A/fr unknown
- 2023-07-03 TW TW112124777A patent/TW202408507A/zh unknown
- 2023-07-03 EP EP23738471.4A patent/EP4551578A1/fr active Pending
-
2024
- 2024-12-11 MX MX2024015363A patent/MX2024015363A/es unknown
- 2024-12-19 US US18/987,316 patent/US20250257075A1/en active Pending
- 2024-12-23 CO CONC2024/0017733A patent/CO2024017733A2/es unknown
- 2024-12-30 CL CL2024004085A patent/CL2024004085A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2024008610A1 (fr) | 2024-01-11 |
| KR20250029239A (ko) | 2025-03-04 |
| CA3261042A1 (fr) | 2024-01-11 |
| AU2023303814A1 (en) | 2024-11-21 |
| EP4551578A1 (fr) | 2025-05-14 |
| PE20250843A1 (es) | 2025-03-21 |
| CN119546612A (zh) | 2025-02-28 |
| AR129819A1 (es) | 2024-10-02 |
| TW202408507A (zh) | 2024-03-01 |
| CL2024004085A1 (es) | 2025-03-21 |
| JP2025522629A (ja) | 2025-07-15 |
| IL316867A (en) | 2025-01-01 |
| US20250257075A1 (en) | 2025-08-14 |
| CR20240563A (es) | 2025-02-14 |
| CO2024017733A2 (es) | 2025-01-13 |
| MX2024015363A (es) | 2025-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA71325A (fr) | Inhibiteur de kras g12c pour le traitement du cancer | |
| IL316867A (en) | Macrocyclic KRAS inhibitors for cancer treatment | |
| MA55959A (fr) | Dosage d'inhibiteur de kras pour le traitement de cancers | |
| MA52780A (fr) | Inhibiteurs de kras g12c pour le traitement du cancer | |
| MA52564A (fr) | Inhibiteurs de kras g12c pour le traitement du cancer | |
| MA56508A (fr) | Inhibiteur d'egfr pour le traitement du cancer | |
| EP4242207A4 (fr) | Inhibiteurs de kras pour le traitement de cancers | |
| EP4467154A4 (fr) | Médicament pour le traitement ou la prévention du cancer | |
| MA71551A (fr) | Composés macrocycles pour le traitement du cancer | |
| MA56050A (fr) | Inhibiteurs hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer | |
| EP3947715A4 (fr) | Procédés et compositions pour le traitement du cancer | |
| EP3894392A4 (fr) | Compositions et procédés pour le traitement du cancer | |
| EP3908601A4 (fr) | Procédés et compositions pour le traitement du cancer | |
| EP4259147A4 (fr) | Polythérapies pour le traitement du cancer | |
| EP4100061A4 (fr) | Polythérapies et biomarqueurs pour le traitement du cancer | |
| EP3947460A4 (fr) | Agents multispécifiques pour le traitement du cancer | |
| EP4149547A4 (fr) | Compositions et méthodes pour le traitement du cancer | |
| EP4319750A4 (fr) | Polythérapies pour le traitement du cancer | |
| EP4229048A4 (fr) | Acylsulfonamides substitués pour le traitement du cancer | |
| MA55093A (fr) | Méthodes et compositions pour le traitement du cancer | |
| EP4373525A4 (fr) | Combinaisons de traitement pour le cancer | |
| EP3968987A4 (fr) | Méthodes et substances pour le traitement du cancer | |
| MA55084A (fr) | Administration d'inhibiteurs de pd-1 pour le traitement du cancer de la peau | |
| IL316829A (en) | Menin-MLL inhibitors for cancer treatment | |
| MA71734A (fr) | Composés pour le traitement du cancer |